2m 2m 2m 2m 2m 2m 2m
PTC Therapeutics (PTCT)
NASDAQ
$82.20+$1.24 (+1.53%)
Price as of Jun 23, 2026 6:42 PM EDT- $6.7BMarket Cap
- 63.23%1-Year Change
- BiotechnologyIndustry
PTC Therapeutics (PTCT)
$82.20+$1.24 (+1.53%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 252.2M -68.74% | 806.8M -13.97% | 937.8M +34.20% | 698.8M +29.75% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 252.2M -68.74% | 806.8M -13.97% | 937.8M +34.20% | 698.8M +29.75% | |
Sales and Marketing Expense | 347.1M +15.36% | 300.9M -9.51% | 332.5M +2.01% | 326.0M +14.08% | |
Research and Development Expense | -455.2M -14.82% | -534.5M -19.82% | -666.6M +2.31% | -651.5M +20.49% | |
Depreciation and Amortization Expense | 38.8M -48.70% | 75.7M -68.02% | 236.6M +83.64% | 128.8M +100.89% | |
Total Operating Expenses | 863.7M -22.14% | 1.1B -19.46% | 1.4B +20.16% | 1.1B +25.54% | |
Operating Profit | 866.9M +386.52% | -302.6M -31.16% | -439.5M -1.77% | -447.4M +19.49% | |
Interest Income | 74.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -152.2M -8.84% | -167.0M +29.27% | -129.2M +42.16% | -90.9M +5.64% | |
Interest Income and Expense and Net | -78.2M -53.20% | -167.0M +29.27% | -129.2M +42.16% | -90.9M +5.64% | |
Total Nonoperating Income and Expense | -18.1M -376.38% | 6.5M -35.40% | 10.1M +120.59% | -49.2M -14.98% | |
Income before Taxes | 696.6M +291.84% | -363.1M -47.84% | -696.1M +18.49% | -587.5M +13.34% | |
Income Taxes | 14.0M +7,840.34% | 176,000 +100.25% | -69.5M +144.14% | -28.5M -611.96% | |
Extraordinary Items | N/A N/A | N/A N/A | 0 N/A | 0 N/A | |
Net Income | 682.6M +287.90% | -363.3M -42.02% | -626.6M +12.09% | -559.0M +6.70% | |
Net Income from Continuing Operations Applicable to Common | 696.6M +291.84% | -363.1M -47.84% | -696.1M +18.49% | -587.5M +13.34% | |
Basic EPS and Net Income | 8.58 +281.40% | -4.73 -43.49% | -8.37 +7.45% | -7.79 +4.85% | |
Diluted EPS and Net Income | 7.78 +264.48% | -4.73 -43.49% | -8.37 +7.45% | -7.79 +4.85% | |
Basic Weighted Average Shares | 79.5M +3.50% | 76.8M +2.68% | 74.8M +4.34% | 71.7M +1.79% | |
Diluted Weighted Average Shares | 88.3M +14.92% | 76.8M +2.68% | 74.8M +4.34% | 71.7M +1.79% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 984.6M +26.28% | 779.7M +31.26% | 594.0M +112.27% | 279.8M +47.50% | |
Short-Term Investments | 960.7M +166.88% | 360.0M +27.32% | 282.7M +116.04% | 130.9M -77.58% | |
Cash and Cash Equivalents and Short-Term Investments | 1.9B +70.69% | 1.1B +29.99% | 876.7M +113.47% | 410.7M -46.89% | |
Total Current Assets | 2.3B +66.52% | 1.4B +12.05% | 1.2B +75.65% | 693.8M -27.30% | |
Accumulated Depreciation | 47.0M +40.87% | 33.4M -34.94% | 51.3M +37.21% | 37.4M +37.52% | |
Property and Plant and Equipment and Net | 55.4M -9.18% | 61.0M -29.99% | 87.1M +19.97% | 72.6M +38.04% | |
Total Long-Term Assets | 55.4M -9.18% | 61.0M -29.99% | 87.1M +19.97% | 72.6M +38.04% | |
Total Assets | 2.9B +70.01% | 1.7B -10.06% | 1.9B +11.14% | 1.7B -11.99% | |
Income Taxes Payable | 4.7M -91.63% | 55.9M 0.00% | 55.9M -45.64% | 102.8M -25.00% | |
Total Short-Term Debt | 286.6M N/A | N/A N/A | N/A N/A | 149.5M 0.00% | |
Total Current Liabilities | 968.4M +66.69% | 581.0M -3.67% | 603.1M +48.46% | 406.2M -20.24% | |
Total Long-Term Debt | 285.4M 0.00% | 285.4M +0.42% | 284.2M -50.29% | 571.7M +102.81% | |
Total Long-Term Liabilities | 13.7M -36.04% | 21.4M +15,095.74% | 141,000 -94.66% | 2.6M +89.73% | |
Total Liabilities | 3.1B +10.74% | 2.8B +3.27% | 2.7B +32.23% | 2.1B +5.99% | |
Retained Earnings | -3.0B -18.72% | -3.6B +11.06% | -3.3B +23.58% | -2.7B +26.65% | |
Total Stockholders Equity | -205.3M -81.30% | -1.1B +34.15% | -818.6M +135.84% | -347.1M -24,236.72% | |
Total Shares Outstanding | 81.5M +4.85% | 77.7M +2.64% | 75.7M +3.56% | 73.1M +3.21% | |
Cash Flow | |||||
Cash from Operating Activities | 711.2M +760.42% | -107.7M -32.02% | -158.4M -55.58% | -356.7M +41.91% | |
Capital Expenditures | 8.9M +36.27% | 6.5M -77.14% | 28.4M -11.18% | 32.0M +13.48% | |
Cash from Investing Activities | -862.0M -2,050.98% | 44.2M +125.00% | -176.7M -160.91% | 290.2M +32.39% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 331.1M +29.40% | 255.9M -60.42% | 646.4M +284.87% | 168.0M +704.48% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | 343.77% +1,016.64% | -37.50% -19.97% | -46.86% -26.80% | -64.03% -7.91% | |
Return on Assets | 29.66% +246.96% | -20.18% -42.01% | -34.80% +13.41% | -30.68% +21.42% | |
Return on Equity | -104.75% -376.31% | 37.91% -64.74% | 107.51% -66.76% | 323.46% +249.23% | |
Revenue Growth | -68.74% +391.96% | -13.97% -140.85% | 34.20% +14.99% | 29.75% -28.24% | |
Current Ratio | 2.35 -0.10% | 2.35 +16.32% | 2.02 +18.32% | 1.71 -8.85% | |
Cash Ratio | 1.02 -24.25% | 1.34 +36.27% | 0.98 +42.99% | 0.69 +84.91% | |
Debt-to-Equity Ratio | -2.79 N/A | N/A N/A | N/A N/A | -2.08 -100.69% | |
Debt-to-Assets Ratio | 0.20 N/A | N/A N/A | N/A N/A | 0.42 +89.98% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow